CO5080764A1 - Metodos para el tratamiento de enfermedades proliferativas - Google Patents

Metodos para el tratamiento de enfermedades proliferativas

Info

Publication number
CO5080764A1
CO5080764A1 CO98075842A CO98075842A CO5080764A1 CO 5080764 A1 CO5080764 A1 CO 5080764A1 CO 98075842 A CO98075842 A CO 98075842A CO 98075842 A CO98075842 A CO 98075842A CO 5080764 A1 CO5080764 A1 CO 5080764A1
Authority
CO
Colombia
Prior art keywords
substituted
alkyl
phenyl
substituents
halo
Prior art date
Application number
CO98075842A
Other languages
English (en)
Inventor
Walter R Bishop
Joseph J Catino
Ronald J Doll
Paul Kirschmeier
Liu Ming
Loretta L Nielsen
David L Cutler
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27385940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5080764(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5080764A1 publication Critical patent/CO5080764A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para tratar enfermedades proliferas en un paciente que necesite dicho tratamiento, comprendido dicho tratamiento administrar concurrente o secuencialmente una cantidad eficaz de (1) un inhibidor de FPT, y (2) un agente antineoplástico y/o terapia de radicación; on la condición de que cuando el inhibidor FPT es un compuesto que tiene la fórmula <EMI FILE="98075842_1" ID="1" IMF=JPEG >Donde la línea de puntos representa un doble enlace opcional; X' es hidrógeno o halo; Y' es hidrógeno, -COOR' donde R´ es alquilo C1 a C12 o alquilo substituido, fenilo substituido, alquilarilo C7 a C 12 o arilalquilo substituido, 2- , 3- o 4-piperidilo o piperidilo N-substituido donde los substituyentes en dicho alquilo C1 a C12 substituido están seleccionados de amino y amino substituido, y los substituyentes en el amino substituido están seleccionados de alquilo C1 a C6, los substituyentes en dicho fenilo substituido y en dicha porción arilo substituida del alquilarilo C7 a C12 están seleccionados de alquilo C1 a C6 y halo y el substituyente en dicho piperidilo N-substituido es alquilo C1 a C4 o -SO2R' donde R' es alquilo C1 a C12 , fenilo, fenilo substituido, arilalquilo C7 a C12 o arilalquilo substituido donde los substituyentes en dicho fenilo substituido y en dicha porción arilo substituida del arilalquilo C7 a C12 están seleccionados de alquilo C1 a C6 y halo; y entonces el agente quimioterapéutico no está seleccionado del grupo que consiste en alcaloides vinca, epipodofillotoxinas, antibióticos de antraciclina, actinomicina D, plicamicina, puromicina, gramicidina D, taxol, colquicina, citocalasina B, emetina, maytansina, amsacrina.
CO98075842A 1997-12-22 1998-12-21 Metodos para el tratamiento de enfermedades proliferativas CO5080764A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99602797A 1997-12-22 1997-12-22
US14352998A 1998-08-28 1998-08-28
US18196998A 1998-10-29 1998-10-29

Publications (1)

Publication Number Publication Date
CO5080764A1 true CO5080764A1 (es) 2001-09-25

Family

ID=27385940

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075842A CO5080764A1 (es) 1997-12-22 1998-12-21 Metodos para el tratamiento de enfermedades proliferativas

Country Status (25)

Country Link
EP (1) EP1041985B1 (es)
JP (1) JP4502503B2 (es)
KR (1) KR100700907B1 (es)
CN (1) CN1129431C (es)
AR (1) AR017440A1 (es)
AT (1) ATE317697T1 (es)
AU (1) AU756762B2 (es)
BR (1) BR9814419A (es)
CA (1) CA2315693C (es)
CL (1) CL2007001889A1 (es)
CO (1) CO5080764A1 (es)
CZ (1) CZ298511B6 (es)
DE (1) DE69833509T2 (es)
DK (1) DK1041985T3 (es)
ES (1) ES2255196T3 (es)
HU (1) HUP0102473A3 (es)
IL (1) IL136462A0 (es)
MY (1) MY137303A (es)
NO (1) NO326832B1 (es)
NZ (1) NZ504928A (es)
PE (1) PE20000042A1 (es)
PT (1) PT1041985E (es)
SK (1) SK285584B6 (es)
TW (1) TW581763B (es)
WO (1) WO1999032114A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
RU2298417C2 (ru) * 1999-11-09 2007-05-10 Сосьете Де Консей Де Решерш Э Д`Аппликасьон Сьентифик (С.К.Р.А.С.) Продукт, включающий ингибитор трансдукции сигналов гетеротримерных протеинов g в комбинации с другим цитостатическим средством, для терапевтического применения при лечении рака
WO2001045740A2 (en) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
EP1267871A2 (en) * 2000-02-29 2003-01-02 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
CA2397475A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
AU2001256166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
JP2003525237A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性アントラサイクリン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
US20030027808A1 (en) * 2000-02-29 2003-02-06 Palmer Peter Albert Farnesyl protein transferase inhibitor combinations with platinum compounds
AU2001235496A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US6645966B2 (en) * 2001-01-22 2003-11-11 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
JP4969016B2 (ja) * 2001-02-15 2012-07-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物
CN101181269A (zh) * 2001-11-30 2008-05-21 先灵公司 法尼基蛋白转移酶抑制剂和其它抗肿瘤剂联合使用在制备抗癌症的药物中的应用
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
WO2008022535A1 (fr) * 2006-08-09 2008-02-28 Tian Jin Tasly Group Co., Ltd. Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique
CN105198758A (zh) * 2015-09-22 2015-12-30 湖南大学 一种高纯度(z)-他莫昔酚的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
DE69120430D1 (de) * 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
JP2767176B2 (ja) * 1992-12-15 1998-06-18 大塚製薬株式会社 抗癌剤
US5637688A (en) * 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
ATE302613T1 (de) * 1995-08-09 2005-09-15 Banyu Pharma Co Ltd Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids
CN1326847C (zh) * 1995-12-22 2007-07-18 先灵公司 三环酰胺类用于抑制g－蛋白功能及治疗增生疾病
HU226646B1 (en) * 1996-03-12 2009-05-28 Pg Txl Company Water soluble pharmaceutical compositions containing taxane derivatives
WO1997036583A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997038697A1 (en) * 1996-04-15 1997-10-23 The Trustees Of The University Of Pennsylvania Sensitization of cells to radiation and chemotherapy
AU2802297A (en) * 1996-04-18 1997-11-07 Merck & Co., Inc. A method of treating cancer
WO1997045412A1 (en) * 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer
WO1998032376A1 (en) * 1997-01-29 1998-07-30 Picker Medical Systems, Ltd. Predictive bolus tracking
ES2287974T3 (es) * 1997-02-18 2007-12-16 Canji, Inc. Terapia genica supresora de tumor y quimioterapia combinadas en el tratamiento neoplasmas.

Also Published As

Publication number Publication date
TW581763B (en) 2004-04-01
EP1041985B1 (en) 2006-02-15
CZ20002236A3 (cs) 2001-04-11
JP2001526224A (ja) 2001-12-18
AU756762B2 (en) 2003-01-23
NO20003229D0 (no) 2000-06-21
MY137303A (en) 2009-01-30
JP4502503B2 (ja) 2010-07-14
SK8982000A3 (en) 2001-04-09
PT1041985E (pt) 2006-07-31
NO20003229L (no) 2000-08-22
PE20000042A1 (es) 2000-02-17
CA2315693C (en) 2010-11-30
ES2255196T3 (es) 2006-06-16
IL136462A0 (en) 2001-06-14
DE69833509D1 (de) 2006-04-20
CL2007001889A1 (es) 2008-01-11
KR100700907B1 (ko) 2007-03-29
HUP0102473A2 (hu) 2002-01-28
AU1907299A (en) 1999-07-12
DK1041985T3 (da) 2006-06-19
CN1129431C (zh) 2003-12-03
NZ504928A (en) 2004-12-24
ATE317697T1 (de) 2006-03-15
NO326832B1 (no) 2009-02-23
DE69833509T2 (de) 2006-10-26
WO1999032114A1 (en) 1999-07-01
CN1284875A (zh) 2001-02-21
SK285584B6 (sk) 2007-04-05
KR20010033452A (ko) 2001-04-25
AR017440A1 (es) 2001-09-05
CZ298511B6 (cs) 2007-10-24
HUP0102473A3 (en) 2003-07-28
BR9814419A (pt) 2000-10-10
CA2315693A1 (en) 1999-07-01
EP1041985A1 (en) 2000-10-11

Similar Documents

Publication Publication Date Title
CO5080764A1 (es) Metodos para el tratamiento de enfermedades proliferativas
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
CY1106602T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
PT723538E (pt) Compostos triciclicos de carbamato uteis para a ainibicao da funcao da proteina g e para o tratamento de doencas proliferativas
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
CY1111153T1 (el) Μορφη οσμοτικης δοσολογιας παρατεταμενης απελευθερωσης
TR200002786T2 (tr) Meloksikam için yeni galenik bir formülasyon.
EA200000711A1 (ru) 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, СПОСОБ ПОЛУЧЕНИЯ ФАРМАЦЕВТИЧЕСКИХ ПРЕПАРАТОВ, СОДЕРЖАЩИХ ЭТИ 11β-ГАЛОГЕН-7α-ЗАМЕЩЕННЫЕ ЭСТРАТРИЕНЫ, И ИХ ПРИМЕНЕНИЕ ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
DE69521994D1 (de) Zusammensetzungen welche dna zerstoerende agentien und p53 enthalten
LU91125I2 (fr) Ranélate den strontium et ses dérivés pharmaceutiquement acceptables (protelos).
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
CY1109364T1 (el) Ενας συνδυασμος που περιλαμβανει κομβρεταστατινη και αντικαρκινικους παραγοντες
DE69710065D1 (de) Androsten-derivate
NZ509244A (en) Treatment regimen for administration of phenylacetylglutamine phenylacetylisoglutamine, and/or phenylacetate
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
TR200001147T2 (tr) Kanser ve makular dejenerasyonun tedavisi için makrolidlerin kullanımı
DE58909850D1 (de) Arzneimittel zur behandlung von krebs, aids und viruserkrankungen
SE0003476D0 (sv) Compounds
GB9907571D0 (en) Compounds
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
ES2058451T3 (es) Un metodo para la preparacion de una composicion farmaceutica.